prikaz prve stranice dokumenta Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry
  Download
PDF 845.89 KB
Scientific paper - Original scientific paper
Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry
Journal of Thrombosis and Thrombolysis, 57 (2023), 1; 39-49. https://doi.org/10.1007/s11239-023-02866-y
Ding, Wern Yew; ...; Kes, Vanja Basic; Kalan, Marica Bracic; Brkljacic, Diana Delic; Knezevic, Aleksandar; Kovacic, Dragan; Nazlić, Jurica; Persic, Viktor; Pivac, Nediljko; Poljakovic, Zdravka

Cite this document

Ding, W. Y., Kes, V. B., Kalan, M. B., Brkljacic, D. D., Knezevic, A., Kovacic, D. ... Poljakovic, Z. (2023). Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry. Journal of Thrombosis and Thrombolysis, 57. (1), 39-49. doi: 10.1007/s11239-023-02866-y

Ding, Wern Yew, et al. "Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry." Journal of Thrombosis and Thrombolysis, vol. 57, no. 1, 2023, pp. 39-49. https://doi.org/10.1007/s11239-023-02866-y

Ding, Wern Yew, Vanja Basic Kes, Marica Bracic Kalan, Diana Delic Brkljacic, Aleksandar Knezevic, Dragan Kovacic, Jurica Nazlić, Viktor Persic, Nediljko Pivac and Zdravka Poljakovic. "Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry." Journal of Thrombosis and Thrombolysis 57, no. 1 (2023): 39-49. https://doi.org/10.1007/s11239-023-02866-y

Ding, W. Y., et al. (2023) 'Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry', Journal of Thrombosis and Thrombolysis, 57(1), pp. 39-49. doi: 10.1007/s11239-023-02866-y

Ding WY, Kes VB, Kalan MB, Brkljacic DD, Knezevic A, Kovacic D, and sur.. Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry. Journal of Thrombosis and Thrombolysis [Internet]. 2023 August 11 [cited 2024 November 16];57(1):39-49. doi: 10.1007/s11239-023-02866-y

W. Y. Ding, et al., "Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry", Journal of Thrombosis and Thrombolysis, vol. 57, no. 1, pp. 39-49, August 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:023108. [Accessed: 16 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry
AuthorWern Yew Ding
Author
...
AuthorVanja Basic Kes
AuthorMarica Bracic Kalan
AuthorDiana Delic Brkljacic
AuthorAleksandar Knezevic
AuthorDragan Kovacic
AuthorJurica Nazlić
AuthorViktor Persic
AuthorNediljko Pivac
AuthorZdravka Poljakovic
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
The 2MACE score was specifically developed as a risk-stratifcation tool in atrial fibrillation (AF) to predict cardiovascular outcomes. We evaluated the predictive ability of the 2MACE score in the GLORIA-AF registry. All eligible patients from phase II/III of the prospective global GLORIA-AF registry were included. Major adverse cardiac events (MACEs) were defned as the composite outcome of stroke, myocardial infarction and cardiovascular death. Cox proportional hazards were used to examine the relationship between the 2MACE score and study outcomes. Predictive capability of the 2MACE score was investigated using receiver-operating characteristic curves. A total of 25,696 patients were included (mean age 71 years, female 44.9%). Over 3 years, 1583 MACEs were recorded. Patients who had MACE were older, with more cardiovascular risk factors and were less likely to be managed using a rhythm-control strategy. The median 2MACE score in the MACE and non-MACE groups were 2 (IQR 1–3) and 1 (IQR 0–2), respectively (p<0.001). The 2MACE score was positively associated with an increase in the risk of MACE, with a score of ≥2 providing the best combination of sensitivity (69.6%) and specificity (51.6%), HR 2.47 (95% CI, 2.21–2.77). The 2MACE score had modest predictive performance for MACE in patients with AF (AUC 0.655 (95% CI, 0.641–0.669)). Our analysis in this prospective global registry demonstrates that the 2MACE score can adequately predict the risk of MACE (defined as myocardial infarction, CV death and stroke) in patients with AF.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Thrombosis and Thrombolysis
Numberingvol. 57, no. 1, pp. 39-49
e-ISSN1573-742X
DOIhttps://doi.org/10.1007/s11239-023-02866-y
URN:NBNurn:nbn:hr:220:023108
Publication2023-08-11
Document URLhttps://link.springer.com/10.1007/s11239-023-02866-y
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-06-17 10:04:05